Please login to the form below

Not currently logged in
Email:
Password:

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn

AstraZeneca acquires TeneoTwo in a deal worth up to $1.27bn

The agreement includes the acquisition of TeneoTwo’s phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, which is currently being assessed in the treatment of relapsed and refractory

Latest news

More from news
Approximately 2 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

    The reason the molecule is called ‘bispecific’ is that it is engineered from not one but two antibodies: one is designed to engage with CD3, which is found on T cells;

  • Taking a lean and careful approach Taking a lean and careful approach

    Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,

  • Deal Watch June 2016 Deal Watch June 2016

    Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding

  • Pharma deals during December 2014 Pharma deals during December 2014

    platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...